Ziopharm Oncology (ZIOP) Posts Q1 Loss of 69c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
ZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities
May 7, 2015 4:41 PM EDTBOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2015, and provided an update on the company's recent activities.
"Through new and existing partnerships with Intrexon and Merck Serono, ZIOPHARM now links a set of immunotherapy programs and technologies with transformative potential in the treatment of cancer," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "Our goal in the coming quarters is to work with our partners to see that these technologies are rapidly integrated and that their promise... More
ZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities
May 7, 2015 4:41 PM EDTBOSTON, May 7, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the first quarter ended March 31, 2015, and provided an update on the company's recent activities.
"Through new and existing partnerships with Intrexon and Merck Serono, ZIOPHARM now links a set of immunotherapy programs and technologies with transformative potential in the treatment of cancer," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "Our goal in the coming quarters is to work with our partners to see that these technologies are rapidly integrated and that their promise... More
